Statement against the use of the USPSTF | 29 NOVEMBER 22
The USPSTF continues to advise against hormone treatment for the prevention of chronic disease in postmenopausal patients.
|
Emphasizes
|
Summary
Importance
Menopause is defined as the cessation of a person’s menstrual cycle. It is defined retrospectively, 12 months after the last menstrual period. Perimenopause, or the transition to menopause, is the period of several years preceding a person’s last menstrual period and is characterized by increased variability in menstrual cycle length and periods of amenorrhea, and often symptoms such as vasomotor dysfunction. The prevalence and the incidence of most chronic diseases (eg, cardiovascular disease, cancer, osteoporosis, and fractures) increase with age, and Americans who reach menopause are projected to live, on average, for another 30 years or more.
Objective
To update the 2017 recommendation, the US Preventive Services Task Force (United States Preventive Services Task Force, USPSTF) commissioned a systematic review to evaluate the benefits and harms of systemic (i.e., oral or transdermal) hormone therapy for the prevention of chronic conditions in postmenopausal people and whether outcomes vary by age or timing of intervention after menopause.
Population
Asymptomatic postmenopausal people considering hormone therapy for primary prevention of chronic medical conditions.
Evaluation of evidence
The USPSTF concludes with moderate certainty that the use of combined estrogen and progestin for primary prevention of chronic conditions in postmenopausal people with an intact uterus has no net benefit. The USPSTF concludes with moderate certainty that the use of estrogen alone for the primary prevention of chronic conditions in postmenopausal people who have had hysterectomy it has no net profit.
Recommendation
- The USPSTF recommends against the use of estrogens and progestogens combinations for primary prevention of chronic conditions in postmenopausal people.
- (Recommendation D) The USPSTF does not recommend the use of estrogen alone for primary prevention of chronic conditions in postmenopausal people who have had a hysterectomy. (Recommendation D)
Summary of recommendations
Importance
The menopause It is defined as the cessation of a person’s menstrual cycle. It is defined retrospectively, 12 months after the last menstrual period. The perimenopause, or menopausal transition, is the period of several years preceding a person’s last menstrual period and is characterized by increased variability in menstrual cycle length and periods of amenorrhea and often symptoms such as vasomotor dysfunction. menopause natural it occurs at a mean age of 51.3 years.
The prevalence and incidence of most chronic diseases (eg, cardiovascular disease, cancer, osteoporosis, and fractures) increase with age, and Americans who reach menopause are expected to live longer on average than Americans another 30 years. However, the excess risk of chronic disease that can be attributed to menopause alone is uncertain.
Evaluating the Size of the USPSTF Net Benefit
The US Preventive Services Task Force (United States Preventive Services Task Force, USPSTF) concludes with moderate certainty that the use of combined estrogen and progestogen for the primary prevention of chronic conditions in postmenopausal people with an intact uterus it has no net profit.
